Zinbryta
Zinbryta Uses, Dosage, Side Effects, Mechanism of Action, How Long Does it Take to Work? Zinbryta is a brand name. Its generic name is Daclizumab.
Introduction
Zinbryta is an immunosuppressive antibody that is used to treat certain types of cancer and multiple sclerosis. It is a humanized monoclonal antibody rapidly approved for use in adults with relapsing forms of multiple sclerosis (MS). Zinbryta is also used in certain types of kidney transplantation for organ rejection.Uses
Zinbryta is used to reduce the risk of organ rejection or relapse in multiple sclerosis in adults. It works by suppressing the immune system to decrease inflammation and prevent the body's rejection of a newly transplanted kidney. In multiple sclerosis, daclizumab can reduce the frequency and severity of exacerbations and slow disease progression.Mechanism of Action
Zinbryta works by blocking the activity of a specific type of T cell, which is a type of white blood cell that is involved in the body’s immune system. The T cells send signals to other cells that help regulate the body’s immune system. By blocking the signals of these T cells, daclizumab reduces the attack made on the cells that protects the myelin sheath around the neurons (nerve cells) in the brain and spinal cord, which is thought to be the cause of multiple sclerosis.How Long Does It Take to Work?
The effects of daclizumab can be seen as early as within the first few weeks of treatment. In clinical trials, individuals with multiple sclerosis taking daclizumab had an average number of relapses per year that was significantly lower than the number observed in people without treatment, suggesting that the drug was reducing the frequency and severity of exacerbations.Absorption
Zinbryta is rapidly and completely absorbed after intravenous or subcutaneous administration. The maximum concentration in the blood occurs approximately 1 to 2 hours after a single dose of daclizumab.Route of Elimination
Zinbryta is eliminated primarily through the kidneys. Its serum half-life is approximately 25 days.Dosage
The recommended dosage of daclizumab for multiple sclerosis is two 150-milligram doses administered intravenously, separated by one month. For kidney transplantation, the recommended dosage is two 150-milligram doses administered intravenously, separated by one month, and then an additional dose of 300 mg administered two weeks after the second dose. Additional doses may be given at eight-week intervals thereafter, if necessary.Administration
Zinbryta is administered intravenously or subcutaneously. It should be given slowly over a 2-minute period.Side Effects
The most common side effects of daclizumab are fever, chills, nausea, vomiting, headache, rash, fatigue, and itching. Other side effects include anemia, increased liver enzymes, and an increased risk of developing certain infections, such as herpes zoster.Toxicity
The effects of an overdose of daclizumab are unknown. However, some of the possible effects could include increased risk of infection or an increased risk of organ rejection. If an overdose is suspected, it is important to seek medical attention immediately.Precautions
Before taking daclizumab, it is important to tell your healthcare provider about any other medications you are taking, any allergies you have, and any medical conditions you may have. You should also tell your healthcare provider if you are pregnant, nursing, or planning to become pregnant. It is also important to avoid live vaccines while taking daclizumab.Interactions
Zinbryta may interact with other medications, such as drugs used to treat cancer, heart disease, and high blood pressure. It is important to tell your healthcare provider about all other medications you are taking, so he or she can determine if it is safe to take daclizumab.Disease Interaction
Zinbryta may interact with certain diseases or conditions, such as active infections, active liver disease, or a history of organ rejection. It is important to tell your healthcare provider about any medical conditions you may have before starting daclizumab.Drug Interaction
Zinbryta may interact with other medications, such as antifungals, antipsychotics, cancer drugs, and immunosuppressive drugs. It is important to tell your healthcare provider about all other medications you are taking, so he or she can determine if it is safe to take daclizumab.Food Interactions
Zinbryta may interact with certain foods or drinks, such as alcohol, large amounts of caffeine, or foods that contain a lot of vitamin D. It is important to talk to your healthcare provider before eating or drinking certain foods while taking daclizumab.Pregnancy Use
Zinbryta is not recommended for use by women who are pregnant, or may become pregnant. It is not known if it is safe for pregnant women to take daclizumab.Lactation Use
Zinbryta is not recommended for use by women who are breastfeeding, or may become breastfeeding. It is not known if it is safe for breastfeeding women to take daclizumab.Acute Overdose
The effects of an overdose of daclizumab are unknown. If an overdose is suspected, it is important to seek medical attention immediately.Contraindications
Zinbryta is contraindicated in patients with a history of hypersensitivity reactions to monoclonal antibodies, as well as in patients who are currently being treated with another immunosuppressive agent.Use Direction
It is important to follow the directions provided by your healthcare provider when taking daclizumab. It is typically given as a single intravenous (IV) infusion over a two-minute period either once every four weeks or as a single subcutaneous injection once every four weeks. The dosage may vary depending on your age, weight, medical history, and other medications you are taking.Storage Condition
Zinbryta should be stored at room temperature, away from light and moisture. Do not freeze the medication.Volume of Distribution
Zinbryta is rapidly and completely absorbed after check intravenous or subcutaneous administration with a volume of distribution of approximately 48 liters/kg. The maximum concentration in the blood occurs approximately 1 to 2 hours after a single dose.Half Life
The half-life of daclizumab is approximately 25 days.Clearance
Zinbryta is cleared from the body primarily through the kidneys. It is removed by both glomerular filtration and active tubular secretion. The renal clearance of daclizumab is approximately 47 mL/min.Here you find in details version of Zinbryta
Some Frequently Asked Questions About Zinbryta
https://www.medicinesfaq.com/brand/zinbryta,
http://www.uniprot.org/uniprot/P01857,
https://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=J00228,
http://www.genome.jp/dbget-bin/www_bget?drug:D03639,
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504469,
https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=190353,
https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201605,
http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000389,
http://www.pharmgkb.org/drug/PA164764446,
http://www.rxlist.com/cgi/generic3/zenapax.htm,
https://www.drugs.com/cdi/daclizumab.html,
https://en.wikipedia.org/wiki/Daclizumab,